1Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys Acta, 1976,455 : 152-162.
2Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a muhidrug-resistant human lung cancer cekk line. Science, 1992,258 : 1650-1654.
3Haimeur.A, Conseil G, Deeley RG, et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curt Drug Metab,2004, 5 : 21-53.
4Renes J, de Vries EG, Nienhuis EF, et al. ATP-and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmaeol. 1999, 126:681-688.
5Leier I, Jedlitschky G, Buchholz U, et al. Transport of glutathione, glucuronate and sulfate conjugates by the MRP gene-encoded conjugate export pump. Biochem J, 1996,314 : 433-437.
6Kale SV, Neely MW, Kala G, et al. The MRF2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic J Biol Chem, 2000, 275 : 33404-33408.
7Evers R, Kool M, Van Deemter L, et al. Drug export activity of the human canalicular muhispecific organic anion transporter in polarized kidney MDCK ceils expressing cMOAT (MRF2) cDNA. J Clin Invest, 1998,101 : 1310-1319.
8Borst P, Kool M, Evers R. Do cMOAT(MRP2), other MRP homologues and LRP play a role in MDR? Semin. Cancer Biol, 1997,8:205-213.
9Leslie EM, Deeley RG, Cole SP. muhidrug resistance protein in toxicology:Role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Tox Appl Pharmacol, 2005,204 : 216-237.
10Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDRI P glycoprotein and muhidrug resistance-associated protein contribute to the bloodcerebrospinal-fluid drug-pemaeability barrer. Proc. Natl Acad Sci USA, 1999,96 : 3900-3905.
2Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [ J ]. Science, 1992, 258 (5088) : 1650- 1654.
3Yin J, Zhang J. Muhidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application [ J ]. Journal of central South university ( medical Sciences) ,2011, 36 (10) : 927-938.
4Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrng resistance associated protein 2 (MRP2/ ABCC2) : its impact on drug disposition [ J]. Adv Drug Deliv Rev, 2002, 54( 10): 1311-1331.
5Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP- binding cassette muhidrng resistance proteins [ J ]. Physiol Rev, 2006, 86 (3) : 849-899.
6Ren XQ, Furukawa T, Aoki S, et al. Glutathione- dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human muhidrug resistance protein [J]. J Biol Chem, 2001, 276(25) : 23197-23206.
7Keppler D. Multidrug resistance proteins ( MRPs, ABCCs) : importance for pathophysiology and drug therapy [J]. Handb Exp Pharmacol, 2011(201) : 299-323.
8Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins : role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense [ J ]. Toxicol Appl Pharmacol, 2005, 204(3) : 216-237.
9Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs. transporters in the liver, small intestine, brain and kidney [J]. J Control Release, 2002, 78(1-3): 43-54.
10Wortelboer HM, Balvers MG, Usta M, et al. Glutathione- dependent interaction of heavy metal compounds with muhidrug resistance proteins MRP1 and MRP2 [ J ]. Environ Toxicol Pharmacol, 2008, 26( 1 ) : 102-108.
